open access

Vol 48, No 4 (2010)
ORIGINAL PAPERS
Published online: 2011-04-12
Submitted: 2011-12-19
Get Citation

Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis.

H Donica, A Malecha-Jędraszek, E Strosławska, A Burska, F Szubstarski
DOI: 10.2478/v10042-010-0088-x
·
Folia Histochem Cytobiol 2010;48(4):603-610.

open access

Vol 48, No 4 (2010)
ORIGINAL PAPERS
Published online: 2011-04-12
Submitted: 2011-12-19

Abstract

The secretory nature of NETs implies the determination of the CgA concentration as a standard marker. The concentration of CgA in plasma correlates with the degree of histopathological differentiation, tumor stage, and is an essential prerequisite for therapy. A retrospective analysis of the results of the plasma CgA concentrations in relation to histopathological and clinical findings (type of NET according to the WHO classification, severity of disease based on the presence of metastases and clinical symptoms) as well as somatostatin receptor scintigraphy was performed in 41 patients with NET. The patients were treated in The Regional Oncology of Lublin from February 2005 to May 2008. Data from the literature and results of this study suggest the use of CgA in the diagnosis and prognosis of NET. Plasma CgA concentration analysed together with histopathological assessment of tumor and the clinical picture is a useful marker in the diagnosis of neuroendocrine tumours. High plasma CgA concentrations may indicate the presence of highly-differentiated NET (WDNEC), and also may indicate the presence of tumor metastasis. The highest CgA concentrations were observed in patients with neuroendocrine tumors associated with carcinoid symptoms and the presence of metastases to the liver.

Abstract

The secretory nature of NETs implies the determination of the CgA concentration as a standard marker. The concentration of CgA in plasma correlates with the degree of histopathological differentiation, tumor stage, and is an essential prerequisite for therapy. A retrospective analysis of the results of the plasma CgA concentrations in relation to histopathological and clinical findings (type of NET according to the WHO classification, severity of disease based on the presence of metastases and clinical symptoms) as well as somatostatin receptor scintigraphy was performed in 41 patients with NET. The patients were treated in The Regional Oncology of Lublin from February 2005 to May 2008. Data from the literature and results of this study suggest the use of CgA in the diagnosis and prognosis of NET. Plasma CgA concentration analysed together with histopathological assessment of tumor and the clinical picture is a useful marker in the diagnosis of neuroendocrine tumours. High plasma CgA concentrations may indicate the presence of highly-differentiated NET (WDNEC), and also may indicate the presence of tumor metastasis. The highest CgA concentrations were observed in patients with neuroendocrine tumors associated with carcinoid symptoms and the presence of metastases to the liver.
Get Citation
About this article
Title

Significance of plasma chromogranin A determination in neuroendocrine tumour (NET) diagnosis.

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 48, No 4 (2010)

Pages

603-610

Published online

2011-04-12

DOI

10.2478/v10042-010-0088-x

Bibliographic record

Folia Histochem Cytobiol 2010;48(4):603-610.

Authors

H Donica
A Malecha-Jędraszek
E Strosławska
A Burska
F Szubstarski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl